How Cell Therapy's Fundamentally Different Model Impacts Patients

Autologous CAR T therapies have transformed cancer care, but their individualized manufacturing model introduces challenges unlike those found in traditional biologics production. Explore today’s market of authorized and marketed therapies, the history behind their development, and the steps required to manufacture a treatment from a patient’s own cells. A closer comparison with biologics manufacturing highlights where CAR T workflows diverge, as well as the bioprocessing practices that have helped shape them. Real-world customer examples also show how manufacturing products and technologies are supporting the reliable delivery of these complex, patient-specific therapies.

Watch to better understand the evolving autologous CAR T manufacturing landscape.